VUH Santaros Klinikos
Welcome,         Profile    Billing    Logout  
 10 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Griskevicius, Laimonas
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
ALLTogether1, NCT04307576 / 2018-001795-38: A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
3
6430
Europe, RoW
Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto
Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins
Leukemia, Acute Lymphoblastic
06/27
06/32
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
NCT03911128: A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
N/A
500
Europe, RoW
Observational
Mats Heyman, Nordic Society for Pediatric Hematology and Oncology, The Swedish Childhood Cancer Foundation, NordForsk
Leukemia, Acute Lymphoblastic
08/28
08/30
Borchmann, Peter
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
HD21, NCT02661503 / 2014-005130-55: for Advanced Stages

Active, not recruiting
3
1500
Europe
Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Brentuximab Vedotin, Dacarbazine, Dexamethasone
University of Cologne
Classical Hodgkin Lymphoma
12/22
09/25
BVB, NCT02191930 / 2013-003990-89: Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Completed
2
70
Europe
B-CAP, Brentuximab Vedotin, Cyclophosphamide, Doxorubicine, Predniso(lo)ne
University of Cologne
Hodgkin Lymphoma
03/22
03/22
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
Pembro-CORE, NCT04838652: Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
2
29
Europe
Pembrolizumab plus Chemotherapy (ICE or DHAP)
University of Cologne
Classical Hodgkin Lymphoma
05/26
05/28
Pembro-FLASH, NCT06045195: Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Not yet recruiting
2
40
Europe
Pembrolizumab
University of Cologne
Hodgkin Lymphoma
01/26
01/28
MTR², NCT05583071: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients with PCNSL

Recruiting
2
20
Europe
Tafasitamab, Lenalidomide, Rituximab, Methotrexate
University of Cologne, Incyte Corporation
Non-Hodgkin Lymphoma
02/27
04/27
NCT03870945: Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

Completed
1/2
12
Europe
MB-CART2019.1 Dose level 1, CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells, MB-CART2019.1 Dose level 2
Miltenyi Biomedicine GmbH, ICON plc
B-cell Non Hodgkin Lymphoma
12/20
05/24
NCT03664635: MB-CART20.1 Lymphoma

Completed
1/2
10
Europe
MB-CART20.1, CD20-targeting CAR T Cells, Anti-CD20 CAR T cells
Miltenyi Biomedicine GmbH
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
09/24
09/24
NCT03893019: MB-CART20.1 Melanoma

Terminated
1
9
Europe
MB-CART20.1, CD20-targeting CAR T cells, anti-CD20 CAR T cells
Miltenyi Biomedicine GmbH, DLR German Aerospace Center
Melanoma (Skin)
01/23
01/23
Szabo, Aniko Sijs
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29

Download Options